Clinical Trials

2,431 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms

NCT00310180 2026-03-18

TAILORx

10,273 enrolled 14 charts

Breast Neoplasms

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

427 enrolled 17 charts

EndocrineNET

Neuroendocrine Tumors

NCT00843882 2026-03-18

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloidOther hematologic neoplasm

247 enrolled 19 charts

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00980460 2026-03-18

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

236 enrolled 18 charts

Gastrointestinal

PRETEXT I Hepatoblastoma

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT01272037 2026-03-18

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT01575548 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

129 enrolled 11 charts

Carcinoma, Renal Cell

NCT01886872 2026-03-18

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02166463 2026-03-18

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

600 enrolled 14 charts 1 FDA

Lymphoid

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT02466971 2026-03-18

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 1 FDA

Plasma cell

Smoldering Multiple Myeloma

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03811002 2026-03-18

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT05654623 2026-03-18

VERITAC-2

624 enrolled 17 charts

Breast Neoplasms

NCT02306161 2026-03-17

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

312 enrolled 14 charts

Sarcoma

Sarcoma, Ewing

NCT02567435 2026-03-17

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

325 enrolled 14 charts

Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT03055013 2026-03-17

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03748641 2026-03-16

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04181827 2026-03-16

CARTITUDE-4

419 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT02445391 2026-03-13

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

415 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT03901963 2026-03-13

AURIGA

200 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT03395197 2026-03-12

TALAPRO-2

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT03462719 2026-03-12

GLOW

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04936308 2026-03-12

SOLSTICE

453 enrolled 25 charts

Arthritis, Psoriatic

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT04205812 2026-03-10

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04524273 2026-03-10

MINT

238 enrolled 36 charts

Myasthenia Gravis

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

406 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05091567 2026-03-10

IMforte

660 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT03336333 2026-03-09

SEQUOIA

590 enrolled 12 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT05171647 2026-03-06

SUNMO

208 enrolled 12 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT01349322 2026-03-05

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

2,354 enrolled 29 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 1 FDA

Dermatologic

Melanoma

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT05316701 2026-03-04

Orca-T

LymphoidMyeloidOther hematologic neoplasm

187 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma